Navigo Proteins’ Precision Capturing™ platform offers a more efficient alternative, based on a single affinity chromatography step. Precision Capturing™ affinity chromatography dramatically simplifies the downstream procedure, strongly reduces number of process steps, effectively shortens development and manufacturing timelines, and in consequence enables robust, scalable and economic industrial manufacturing processes.
This way, notably in late stage and for market supply Precision Capturing™ affinity chromatography significantly reduces time, risk and COGS.
Navigo Proteins envisions affinity chromatography as a generic platform process for any, even complex biopharmaceutical product. We provide solutions for all biological product classes, including antibodies, antibody fragments, fusion proteins, enzymes, hormones, blood factors, as well as vaccines, viral vectors, virus-like particles, or even entire cells.
We discover and develop affinity ligands with best-in-class binding capacity and selectivity, as well as chemical and caustic stability. Our affinity chromatography ligands are fully patent protected to our customers.
Navigo Proteins co-operates with renowned partners for the GMP-compliant coupling of our ligands to supply regulatory well-accepted resin or membrane-based ready-to-use chromatography matrices.
Navigo Proteins provides a solution for all these requirements by having developed innovative, proprietary next generation Protein A affinity ligands which are designed to meet these requirements. Our Protein A ligands have both higher caustic stability and dynamic binding capacity, compared to even commercially available gold standard market products.
Affilin® ligands offer fully adjustable specificities, affinities and pH elution profiles. The selection and screening processes delivers protein ligands specific for any given target, yet literally without any off-target activity. Our Affilin® ligands possess high caustic and chemical stability to cope with CIP and sanitization procedures under harsh conditions. Moreover, and in contrast to antibodies, Affilin® ligands are very small (~8kDa) and stable proteins, but they are broadly engineerable, including easy multimerization for improved capacity, flexible linker design and site-specific, 3D-oriented chemistry. Finally, our Affilin® ligands are amenable to economical production in E.coli at industrial scale.
Navigo Non-Antibody Affinity Ligands have extraordinarily stability that copes with industrial routines and expectations
Starting point is a selected scaffold protein with favorable characteristics such as:
• small size (<10kDa)
• very high thermal, proteolytic and caustic stability
• no post-translational modifications
• no cysteines
• cost effective production in E.coli
High quality and diverse binder libraries are generated at the genetic level from the starting protein scaffold by randomization of a number of surface-exposed amino acid residues. Each randomized position comprises all possible natural amino acids (except Cysteine) which leads to large combinatorial libraries with complexities from 1010 to 1012 variants, depending on the specific display format used.
Selection and Screening
For the subsequent selection process, both phage display and ribosome display are available. The following automated, robotics-assisted high-throughput screening (HTS) key technology identifies Affilin® ligand-enriched selection pools. Further rigorous screening rounds finally yield those Precision Capturing™ ligands with the desired properties and suitable for large-scale industrial use.
To do so, Navigo Proteins has tailored an HTS platform which allows a flexible assay design and selection, based on multiple parameters. Rapid screening of well beyond 10.000 Affilin® binders per day identifies a set of diverse Precision Capturing candidates from which we select the most promising leads for further development.
High-throughput Screening at Navigo comprises the entire hit-selection and identification process, maximizing throughput and clone diversity
Navigo Proteins pursues a stringent policy of patenting its proprietary products and technology. With over 100 patents granted and dozens of applications pending, our assets are secured in all major markets. Moreover, this provides our clients with a safe, undisputed IP protection and thus competitiveness and long-term planning security for any licensed Navigo products and technology.
A thorough functional characterization of Precision Capturing™ ligands from the selection process is absolutely crucial to identify the most promising lead candidates for further development. This comprises a range of biochemical, biophysical as well as functional protein characterization steps in house. In particular, chemical and caustic stability (in static and cyclic performance) are important criteria. Another central criterion is binding capacity (i.e. DBC10, SBC) of the final Precision Capturing ligand-coupled matrix and its process performance in step yields, elution pH and host-cell protein or DNA reduction.